questionsmedicales.fr
Phénomènes génétiques
Structures génétiques
Génome
Composants de génome
Gènes
Gènes régulateurs
Gènes switch
Gènes switch : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gènes switch : Questions médicales les plus fréquentes",
"headline": "Gènes switch : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gènes switch : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-19",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gènes switch"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Gènes régulateurs",
"url": "https://questionsmedicales.fr/mesh/D005809",
"about": {
"@type": "MedicalCondition",
"name": "Gènes régulateurs",
"code": {
"@type": "MedicalCode",
"code": "D005809",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.425"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gènes switch",
"alternateName": "Genes, Switch",
"code": {
"@type": "MedicalCode",
"code": "D005812",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Martin Fussenegger",
"url": "https://questionsmedicales.fr/author/Martin%20Fussenegger",
"affiliation": {
"@type": "Organization",
"name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland; University of Basel, Faculty of Life Science, Basel, Switzerland. Electronic address: fussenegger@bsse.ethz.ch."
}
},
{
"@type": "Person",
"name": "Ana Palma Teixeira",
"url": "https://questionsmedicales.fr/author/Ana%20Palma%20Teixeira",
"affiliation": {
"@type": "Organization",
"name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland."
}
},
{
"@type": "Person",
"name": "Jin Wang",
"url": "https://questionsmedicales.fr/author/Jin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Physics and Applied Mathematics, State University of New York at Stony Brook, Stony Brook, New York 11794, USA."
}
},
{
"@type": "Person",
"name": "Jörg S Hartig",
"url": "https://questionsmedicales.fr/author/J%C3%B6rg%20S%20Hartig",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany; Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany. Electronic address: joerg.hartig@uni-konstanz.de."
}
},
{
"@type": "Person",
"name": "Omer Gokcumen",
"url": "https://questionsmedicales.fr/author/Omer%20Gokcumen",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A novel method for real-time analysis of the complement C3b:FH:FI complex reveals dominant negative",
"datePublished": "2022-12-28",
"url": "https://questionsmedicales.fr/article/36643920",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.1028760"
}
},
{
"@type": "ScholarlyArticle",
"name": "CNS Inflammation as the First Sign of Complement Factor I Deficiency.",
"datePublished": "2023-12-22",
"url": "https://questionsmedicales.fr/article/38134378",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1212/NXI.0000000000200191"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hot Spot of Complement Factor I Rare Variant p.Ile357Met in Patients With Hemolytic Uremic Syndrome.",
"datePublished": "2024-02-27",
"url": "https://questionsmedicales.fr/article/38423159",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1053/j.ajkd.2023.12.021"
}
},
{
"@type": "ScholarlyArticle",
"name": "Model-based interspecies scaling for predicting human pharmacokinetics of CB 4332, a complement factor I protein.",
"datePublished": "2024-06-28",
"url": "https://questionsmedicales.fr/article/38945365",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.xphs.2024.06.022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comprehensive functional characterization of Complement factor I rare variant genotypes identified in the SCOPE Geographic Atrophy cohort.",
"datePublished": "2024-06-07",
"url": "https://questionsmedicales.fr/article/38852887",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jbc.2024.107452"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gènes régulateurs",
"item": "https://questionsmedicales.fr/mesh/D005809"
},
{
"@type": "ListItem",
"position": 8,
"name": "Gènes switch",
"item": "https://questionsmedicales.fr/mesh/D005812"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gènes switch - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gènes switch",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gènes switch",
"description": "Comment identifier un gène switch ?\nQuels tests sont utilisés pour les gènes switch ?\nLes gènes switch sont-ils visibles sur une analyse génétique ?\nPeut-on détecter des mutations dans les gènes switch ?\nQuels marqueurs sont associés aux gènes switch ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gènes switch",
"description": "Quels symptômes sont liés aux gènes switch ?\nLes gènes switch affectent-ils le développement ?\nPeut-on observer des anomalies dues aux gènes switch ?\nLes gènes switch influencent-ils le comportement ?\nY a-t-il des symptômes neurologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gènes switch",
"description": "Peut-on prévenir les maladies liées aux gènes switch ?\nQuels modes de vie peuvent aider à prévenir ces maladies ?\nLes conseils génétiques sont-ils utiles ?\nY a-t-il des vaccins pour prévenir les effets des gènes switch ?\nComment le suivi médical contribue-t-il à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gènes switch",
"description": "Comment traiter les dysfonctionnements des gènes switch ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des essais cliniques pour ces traitements ?\nLes traitements sont-ils efficaces ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gènes switch",
"description": "Quelles complications peuvent survenir avec les gènes switch ?\nLes gènes switch peuvent-ils causer des maladies héréditaires ?\nY a-t-il des risques de transmission familiale ?\nLes complications sont-elles réversibles ?\nComment les gènes switch affectent-ils la longévité ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gènes switch",
"description": "Quels facteurs de risque sont associés aux gènes switch ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il les gènes switch ?\nLes facteurs génétiques jouent-ils un rôle ?\nLes infections peuvent-elles affecter les gènes switch ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Complement+Factor+I&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un gène switch ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques comme le séquençage et l'analyse d'expression génique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les gènes switch ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de PCR et des analyses de microarray sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les gènes switch sont-ils visibles sur une analyse génétique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être détectés indirectement par l'expression des gènes qu'ils régulent."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les gènes switch ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations peuvent être identifiées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux gènes switch ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs épigénétiques comme les méthylations peuvent indiquer leur activité."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux gènes switch ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon les gènes régulés, incluant des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les gènes switch affectent-ils le développement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils jouent un rôle crucial dans le développement embryonnaire et cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies dues aux gènes switch ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent se manifester par des malformations congénitales ou des cancers."
}
},
{
"@type": "Question",
"name": "Les gènes switch influencent-ils le comportement ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes switch peuvent affecter des traits comportementaux et cognitifs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines dysrégulations peuvent entraîner des troubles neurologiques variés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux gènes switch ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par le dépistage génétique et des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels modes de vie peuvent aider à prévenir ces maladies ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est bénéfique."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques aident à évaluer les risques et à planifier des actions préventives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir les effets des gènes switch ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour les gènes switch."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical contribue-t-il à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet de détecter précocement des anomalies et d'intervenir rapidement."
}
},
{
"@type": "Question",
"name": "Comment traiter les dysfonctionnements des gènes switch ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblés peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques pour ces traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux essais cliniques explorent des thérapies pour les gènes switch."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon le type de gène switch et la pathologie associée."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent inclure des réactions immunitaires ou des complications."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les gènes switch ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des troubles métaboliques et des malformations."
}
},
{
"@type": "Question",
"name": "Les gènes switch peuvent-ils causer des maladies héréditaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes switch sont impliqués dans des maladies héréditaires complexes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de transmission familiale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les gènes switch peuvent être transmis et affecter plusieurs membres d'une famille."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Comment les gènes switch affectent-ils la longévité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements peuvent réduire l'espérance de vie en augmentant le risque de maladies."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux gènes switch ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs environnementaux, génétiques et comportementaux peuvent influencer leur activité."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter l'expression des gènes switch et le risque de maladies."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les gènes switch ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme ou l'alimentation peuvent moduler leur activité."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent prédisposer à des dysfonctionnements des gènes switch."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles affecter les gènes switch ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent altérer l'expression des gènes switch et provoquer des maladies."
}
}
]
}
]
}
Age-related macular degeneration (AMD) is linked to 2 main disparate genetic pathways: a chromosome 10 risk locus and the alternative pathway (AP) of complement. Rare genetic variants in complement fa...
Complement factor I (CFI) deficiency is a rare autosomal recessive inborn error of immunity. In this report, we highlight that complete CFI deficiency may present with isolated and severe CNS inflamma...
This is a case description of a young girl with severe longitudinal transverse myelitis treated with aggressive immunotherapy that included eculizumab. Published cases of CFI-associated CNS inflammati...
A primary immunodeficiency panel revealed 2 germline pathogenic variants in the CFI gene. Further complement testing of the index case and her family confirmed complete CFI deficiency....
We describe a unique case of severe spinal inflammation secondary to complete CFI deficiency. Although rare, isolated CNS inflammation may be the primary manifestation of complete CFI deficiency. To h...
Atypical haemolytic uremic syndrome (aHUS) is a rare kidney disease due to a dysregulation of the complement alternative pathway (AP). Complement factor I (CFI) negatively regulates the AP and CFI gen...
Interspecies scaling of the pharmacokinetics (PK) of CB 4332, a 150 kDa recombinant complement factor I protein, was performed using traditional and model-based approaches to inform first-in-human dos...
Rare variants (RVs) in the gene encoding the regulatory enzyme complement factor I (CFI; FI) that reduce protein function or levels increase age-related macular degeneration (AMD) risk. A total of 335...
Interferon-beta (IFNβ), the most widely prescribed medication for multiple sclerosis, is generally considered safe. Nevertheless, rare serious and/or life-threatening side effects have been reported s...
We report thrombotic microangiopathy in a 28-year-old male receiving interferon-beta treatment for multiple sclerosis....
After three years of starting interferon beta therapy, the patient presented with malignant hypertension causing seizures, rapidly progressive renal failure requiring haemodialysis and haemolytic anae...
IFNβ treatment may cause complement factor I deficit, which can lead to thrombotic microangiopathy and severe renal failure....
Dense connective tissues (DCTs) such as tendon, ligament, and cartilage are important stabilizers and force transmitters in the musculoskeletal system. The healing processes after DCT injuries are hig...
Quantitative mass spectrometry (QMS) profiling of tissue biopsies from the inflammatory phase of healing (n = 40 patients) and microdialysates from the proliferative phase of healing (n = 28 patients)...
The QMS profiling of tissue biopsies from the inflammatory phase of healing identified 769 unique proteins, and microdialysates from the proliferative phase of healing identified 1423 unique proteins ...
The results of the current studies characterized underlying inflammatory- and proliferative healing mechanisms by which CFD potentially improved tendon repair. These findings may lead to improved indi...
http://clinicaltrials.gov, identifiers NCT02318472, NCT01317160....
Advanced age-related macular degeneration (AAMD) risk is associated with rare complement Factor I (FI) genetic variants associated with low FI protein levels (termed 'Type 1'), but it is unclear how v...
Collective prevalence of Type 1 CFI rare variant genotypes were examined in four European AAMD datasets. Collective minor allele frequencies (MAFs) were sourced from the natural history study SCOPE, t...
Type 1 CFI rare variants were enriched in all European AAMD cohorts, with odds ratios (ORs) ranging between 3.1 and 7.8, and a greater enrichment was observed in dry AMD from FINBB (OR 8.9, 95% CI 1.4...
The relationship between Type 1 CFI rare variants increasing odds of AAMD are well established in Europeans, however the lack of broader genetic data in AAMD has adverse implications for clinical deve...
While numerous membrane-bound complement inhibitors protect the body's cells from innate immunity's autoaggression, soluble inhibitors like complement factor I (FI) are rarely produced outside the liv...
Of the four human immunoglobulin G (IgG) subclasses, IgG4 is considered the least inflammatory, in part because it poorly activates the complement system. Regardless, in IgG4 related disease (IgG4-RD)...